Abstract Library

#4497 Complex management of a long-term gastrinoma survivor with multimodal treatment approaches

Introduction: The prognosis of pancreatic gastrinomas is influenced by tumour burden, extent of metastasis, and treatment response, with 5-year survival rates ranging from 20% to 40%. Treatment for well-differentiated tumours typically include locoregional therapies, long-acting somatostatin analogues, molecular targeted agents, radionuclides, and chemotherapy.

Conference:

Presenting Author: Puscasu A

Authors: Puscasu A, Miron M, Croitoru A,

Keywords: gastrinoma, neuroendocrine tumour, long survival, complex management,

#4473 Somatostatin analogue delayed the recrudescence of stomach NET: A real-world study

Introduction: Type 1 gastric NENs (g-NENs) are common and relapse easily. Somstostatin analogues (SSAs) can inhibit gastrin secretion and cell proliferation. While the usage of SSAs in g-NENs is still controversial.

Conference:

Presenting Author: Cai W

Authors: Cai W, Zhang J, Ge W, Hu H,

Keywords: somatostatin analogue, Type 1 gastric NEN, real-world study,

#4445 Pancreatico-duodenal gastrinomas: Surgical management and late results – 50 years' experience in a single centre

Introduction: Gastrinomas are one of the less frequent and elusive variety of neuroendocrine tumours (NET) of the upper digestive tract and pancreas, clinically expressed with a Zollinger-Ellison syndrome (ZES), possibly associated to a Multiple Endocrine Neoplasia type 1 (MEN1).

Conference:

Presenting Author:

Authors: Milanetto A, Veronese E, de Carlo E, Pasquali C,

Keywords: gastrinoma, men1, net,

#4354 Analysis of gastric NENS in the Czech neuroendocrine tumour registry (2009-2024)

Introduction: Czech Neuroendocrine Tumour Registry is collecting data of NEN patients and their treatment since 2009. We have already analysed SI NENs, pancreatic and thymic NENs. Now we focused on analysis of gastric NENs.

Conference:

Presenting Author:

Authors: Barkmanova J, Sedlackova E,

Keywords: registry, gastric neuroendocrine neoplasia,

#4351 Outcomes of lobar and sub-lobar resection for lung neuroendocrine tumours (LNETs, carcinoids) – An ENETS CoE experience

Introduction: LNETs are rare tumours accounting for 1–2% of all lung cancers.

Conference:

Presenting Author:

Authors: Hojerat R, Idaiss I, Aviel G, Korach A, Bel-Ange A,

Keywords: lung neuroendocrine tumour, pulmonary carcinoid, lobar resection, sub-lobar resection, pro-gastrin-releasing peptide,